NASH – The Urgent Need for Better Disease Models and New Therapies

by Karen O'Hanlon Cohrt | Apr 4, 2023 | Disease Models

Welcome to our new mini-series about liver organoids. In Part 1, we focus on non-alcoholic steatohepatitis (NASH), a severe and prevalent form of non-alcoholic fatty liver disease for which no drugs have been approved. We look at the current treatment landscape for...

Better Blood Brain Barrier Models Are Urgently Needed for Modern Therapeutic Advances

by Karen O'Hanlon Cohrt | Feb 19, 2023 | Trends

Welcome to Part 4 of our series about the blood brain barrier (BBB)! Here, we highlight the rising global burden of neurological disorders, and recap on the challenges surrounding drug safety and toxicity in relation to the BBB. As industry speeds ahead with novel...

Sources of cells for modeling the human BBB — 4 considerations

by Karen O'Hanlon Cohrt | Jan 26, 2023 | Trends

Welcome to Part 3 of our blog series covering the blood brain barrier (BBB). In Part 1, we looked briefly at how the BBB was discovered and presented what we currently know about its composition and functions. Part 2 focused on the need for reliable BBB models in drug...

In Vitro Blood Brain Barrier Models for Drug Development

by Karen O'Hanlon Cohrt | Dec 18, 2022 | Trends

Welcome back to our blog series about the blood brain barrier (BBB). In Part 1, we provided a brief history on the discovery of the BBB, and introduced what we currently know about its composition and biological functions. In Part 2, we explain why reliable BBB models...

What is the Blood Brain Barrier? Part 1 of a Series

by Karen O'Hanlon Cohrt | Nov 18, 2022 | Trends

Welcome to our new blog series about the blood brain barrier (BBB)! In Part 1, we will give a brief history on the discovery of the BBB, as well as introduce what we know about its composition and biological functions. The blood brain barrier or BBB is a highly...